Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2011

01-10-2011 | Research Article

p53 regulates Ki-67 promoter activity through p53- and Sp1-dependent manner in HeLa cells

Authors: Mei-Juan Wang, Dong-Sheng Pei, Guo-Wei Qian, Xiao-Xing Yin, Qian Cheng, Lian-Tao Li, Hui-Zhong Li, Jun-Nian Zheng

Published in: Tumor Biology | Issue 5/2011

Login to get access

Abstract

The expression of the human Ki-67 protein, which is strictly associated with cell proliferation, is regulated by a variety of cellular mediators. In this study, we studied the effects of p53 on Ki-67 promoter in HeLa cells using luciferase reporter assay. The results showed that: (1) p53 inhibited Ki-67 promoter activity in a dose-dependent manner, (2) the p53-binding motifs mediated part of the transcriptional repression of Ki-67 promoter through a sequence-specific interaction with p53, (3) p53 was able to repress the Sp1-stimulated Ki-67 promoter activity, and (4) the Sp1-binding sites were responsible for the p53-mediated transcriptional repression of Ki-67 promoter. In conclusion, p53 inhibited Ki-67 promoter activity via p53- and Sp1-dependent pathways, and the interaction between p53 and Sp1 might be involved in the transcriptional regulatory mechanisms.
Literature
1.
2.
Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localization of gene for human p53 tumour antigen to band 17p13. Nature. 1986;320:84–5.PubMedCrossRef
3.
4.
Olivier M, Hussain SP, Caron de Fromentel C, Hainaut P, Harris CC. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ. 2004;157:247–70.PubMed
5.
6.
Scheffenr M, Münger K, Byrne JC, Howley P. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA. 1991;88:5523–7.CrossRef
7.
Gerdes J, Lemeke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the moncelonal antibody ki67. J Immunol. 1984;133:1710–5.PubMed
8.
Schlzen T, Gerdes J. The Ki-67 protein:from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRef
9.
Shirendeb U, Hishikawa Y, Moriyama S, Win N, Thu MM, Mar KS, et al. Human papillomavirus infection and its possible correlation with p53 expression in cervical cancer in Japan, Mongolia, and Myanmar. Acta Histochem Cytochem. 2009;42:181–90.PubMedCrossRef
10.
Gorczyca W, Markiewski M, Kram A. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction. Virchows Arch. 1995;426:229–33.PubMedCrossRef
11.
Iamaroon A, Khemaleelakul U, Pongsiriwet S, Pintong J. Co-expression of p53 and Ki67 and lack of EBV expression in oral squamous cell carcinoma. J Oral Pathol Med. 2004;33:30–6.PubMedCrossRef
12.
Georgescu CV, Săftoiu A, Georgescu CC, Ciurea R, Ciurea T. Correlations of proliferation markers, p53 expression and histological findings in colorectal carcinoma. J Gastrointestin Liver Dis. 2007;16:133–9.PubMed
13.
Halm U, Tannapfel A, Breitung B, Breidert M, Wittekind CW, Mössner J. Apoptosis and cell proliferation in the metaplasiadysplasia-carcinoma-sequence of Barrett's esophagus. Hepatogastroenterology. 2000;47:962–6.PubMed
14.
Krishnadath KK, Reid BJ, Wang KK. Biomarkers in Barrett esophagus. Mayo Clin Proc. 2001;76:438–46.PubMedCrossRef
15.
Lopes CV, Pereira-Lima J, Hartmann AA. p53 immunohistochemical expression in Barrett's esophagus before and after endoscopic ablation by argon plasma coagulation. Scand J Gastroenterol. 2005;40:259–63.PubMedCrossRef
16.
Tian H, Qian GW, Chen FF, Di JH, Zhang BF, Pei DS, et al. A critical role of Sp1 transcription factor in regulating the human Ki-67 gene expression. Tumor Biol. 2010;32:273–83.CrossRef
17.
Hooghe B, Hulpiau P, Roy FV, Bleser PD. ConTta: a promoter alignment analysis tool for dentification of transcription factor binding sites across species. Nucleic Acids Res. 2008;36:128–32.CrossRef
18.
Matlashewski G, Banks L, Pim D, Crawford L. Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur J Biochem. 1986;154:665–72.PubMedCrossRef
19.
Króliczak W, Pietrzak M, Puzianowska-Kuznicka M. p53-dependent suppression of the human cacyclin gene (S100A6) the role of Sp1 and of NFκB. Acta Biochim Pol. 2008;55:559–70.PubMed
20.
21.
22.
Cuesta A, Zambrano A, Royo M, Pascual A. The tumour suppressor p53 regulates the expression of amyloid precursor protein (APP). Biochem J. 2009;418:643–50.PubMedCrossRef
23.
Shirley SH, Rundhaug JE, Tian J, Cullinan-Ammann N, Lambertz I, Conti CJ, et al. Transcriptional regulation of estrogen receptor-α by p53 in human breast cancer cells. Cancer Res. 2009;69:3404–14.CrossRef
24.
Bocangel D, Sengupta S, Mitra S, Bhakat KK. p53-Mediated down-regulation of the human DNA repair gene O6-Methylguanine-DNA Methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res. 2009;29:3741–50.PubMed
25.
St Clair S, Giono L, Varmeh-Ziaie S, Resnick-Silverman L, Liu WJ, Padi A, et al. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol Cell. 2004;16:725–36.PubMedCrossRef
26.
Li B, Lee MY. Transcriptional regulation of the human DNA polymerase δ catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1. J Biol Chem. 2001;276:29729–39.PubMedCrossRef
27.
Farmer G, Friedlander P, Colgan J, Manley JL, Prives C. Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein. Nucleic Acids Res. 1996;24:4281–8.PubMedCrossRef
28.
Glait C, Tencer L, Ravid D, Sarfstein R, Liscovitch M, Werner H. Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1- and p53-dependent pathways. Exp Cell Res. 2006;312:3899–908.PubMedCrossRef
29.
Farmer G, Colgan J, Nakatani Y, Manley JL, Prives C. Functional interaction between p53, the TATA-binding protein (TBP), and TBP-associated factors in vivo. Mol Cell Biol. 1996;16:4295–304.PubMed
30.
Borellini F, Glazer RI. Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J Biol Chem. 1993;268:7923–8.PubMed
31.
Torgeman A, Mor-Vaknin N, Zelin E, Ben-Aroya Z, Löchelt M, Flügel RM, et al. Sp1-p53 heterocomplex mediates activation of HTLV-I long terminal repeat by 12-O-tetradecanoylphorbol-13-acetate that is antagonized by protein kinase C. Virology. 2001;281:10–20.PubMedCrossRef
32.
Koutsodontis G, Vasilaki E, Chou WC, Papakosta P, Kardassis D. Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis. Biochem J. 2005;389:443–55.PubMedCrossRef
Metadata
Title
p53 regulates Ki-67 promoter activity through p53- and Sp1-dependent manner in HeLa cells
Authors
Mei-Juan Wang
Dong-Sheng Pei
Guo-Wei Qian
Xiao-Xing Yin
Qian Cheng
Lian-Tao Li
Hui-Zhong Li
Jun-Nian Zheng
Publication date
01-10-2011
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2011
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0191-4

Other articles of this Issue 5/2011

Tumor Biology 5/2011 Go to the issue

Research Article

Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin’s lymphoma of mucosa-associated lymphoid tissue type

Research Article

BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells

Research Article

Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells

Research Article

Role of transforming growth factor-β1 −509 C/T promoter polymorphism in gastric cancer in south Indian population

Research Article

A combination of 2-deoxy-d-glucose and 6-aminonicotinamide induces oxidative stress mediated selective radiosensitization of malignant cells via mitochondrial dysfunction

Research Article

Quantitative expression analysis of apoptotic/antiapoptotic genes and association with immunolocalization of BAX and BCL-2 in peripheral and central giant cell lesions of the jaws
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits